Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent

Guo, 2020, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status, Mil Med Res, 7, 1 McIntosh, 1974, 85 Yin, 2018, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology, 23, 130, 10.1111/resp.13196 Thomson, 2020, COVID-19 social distancing, ACE 2 receptors, protease inhibitors and beyond?, Int J Clin Pract, 10.1111/ijcp.13503 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med, 10.1016/S2213-2600(20)30076-X Greener, 2017, Old drug, new tricks: realising the potential of repurposing, Prescriber, 28, 34, 10.1002/psb.1618 Pushpakom, 2019, Drug repurposing: progress, challenges and recommendations, Nat Rev Drug Discov, 18, 41, 10.1038/nrd.2018.168 Pindiprolu, 2020, Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19, Med Hypotheses, 109765 Zhang, 2012, The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles, Biomaterials, 33, 679, 10.1016/j.biomaterials.2011.09.072 Deng, 2020, Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, J Infect, 10.1016/j.jinf.2020.03.002 Favalli, 2020, Baricitinib for COVID-19: a suitable treatment?, Lancet Infect Dis, 10.1016/S1473-3099(20)30262-0 Colson, 2020, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, 105932 Cai, 2020, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, 10.1016/j.eng.2020.03.007 Elfiky, 2020, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study, Life Sci, 117592 Cao, 2020, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, 10.1056/NEJMoa2001282 Ko, 2020, Arguments in favour of remdesivir for treating SARS-CoV-2 infections, Int J Antimicrob Agents, 10.1016/j.ijantimicag.2020.105933 Elfiky, 2020, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19, Life Sci, 117477 Jang, 2018, Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function, J Virol, 92, e01441, 10.1128/JVI.01441-18 Ko, 2020, Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19, bioRxiv De Clercq, 2006, Potential antivirals and antiviral strategies against SARS coronavirus infections, Expert Rev Anti-infective Therapy, 4, 291, 10.1586/14787210.4.2.291 Jain, 2015, Optimization of artemether-loaded NLC for intranasal delivery using central composite design, Drug Deliv, 22, 940, 10.3109/10717544.2014.885999 Weber, 2014, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art, Eur J Pharm Biopharm, 86, 7, 10.1016/j.ejpb.2013.08.013 Beloqui, 2016, Nanostructured lipid carriers: promising drug delivery systems for future clinics, Nanomed Nanotechnol Biol Med, 12, 143, 10.1016/j.nano.2015.09.004 Patlolla, 2010, Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers, J Control Release, 144, 233, 10.1016/j.jconrel.2010.02.006 Shao, 2015, Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA, Int J Nanomed, 10, 1223, 10.2147/IJN.S77837